Personalis And Yale Cancer Center Collaboration For Clinical Trial Titled "A single arm phase II trial of circulating tumor DNA-guided adjuvant therapy with elacestrant in hormone receptor positive HER2 negative breast cancers at risk for late recurrence (CATE),"
Author: Benzinga Newsdesk | September 10, 2025 03:10pm